[go: up one dir, main page]

SG11201407652RA - Production cell line enhancers - Google Patents

Production cell line enhancers

Info

Publication number
SG11201407652RA
SG11201407652RA SG11201407652RA SG11201407652RA SG11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA SG 11201407652R A SG11201407652R A SG 11201407652RA
Authority
SG
Singapore
Prior art keywords
international
new york
production cell
edem2
cell
Prior art date
Application number
SG11201407652RA
Inventor
Gang Chen
Darya Burakov
Dipali Deshpande
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201407652RA publication Critical patent/SG11201407652RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181253 A1 (51) International Patent Classification: C07K16/00 (2006.01) C12N15/79 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043116 29 May 2013 (29.05.2013) English English (30) Priority Data: 61/652,549 13/904,587 29 May 2012 (29.05.2012) US 29 May 2013 (29.05.2013) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). (72) Inventors: CHEN, Gang; 1600 Fox Tail Lane, Yorktown Heights, New York 10598 (US). BURAKOV, Darya; 10 Ashton Road, Yonkers, New York 10705 (US). DESH- PANDE, Dipali; 62 Eldorado Court, White Plains, New York 10603 (US). (74) Agent: JOHNSON, Mary C.; Regeneron Pharmaceutic­ als, Inc., Ill Old Saw Mill River Road, Tarrytown, New York 10591 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) CJ i-H 00 ^ (54) Title: PRODUCTION CELL LINE ENHANCERS 5 (57) Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the fS yield of useful multi-subunit a protein. Thus, the present invention provides for production cell lines, such as the canonical mam- malian biopharmaceutical production cell - the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed (5T is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1 -encoding polynucleotide. Improved titers S of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.
SG11201407652RA 2012-05-29 2013-05-29 Production cell line enhancers SG11201407652RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652549P 2012-05-29 2012-05-29
US13/904,587 US9079954B2 (en) 2012-05-29 2013-05-29 Production cell line enhancers
PCT/US2013/043116 WO2013181253A1 (en) 2012-05-29 2013-05-29 Production cell line enhancers

Publications (1)

Publication Number Publication Date
SG11201407652RA true SG11201407652RA (en) 2014-12-30

Family

ID=49670701

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407652RA SG11201407652RA (en) 2012-05-29 2013-05-29 Production cell line enhancers
SG10201606654XA SG10201606654XA (en) 2012-05-29 2013-05-29 Production cell line enhancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201606654XA SG10201606654XA (en) 2012-05-29 2013-05-29 Production cell line enhancers

Country Status (20)

Country Link
US (9) US9079954B2 (en)
EP (3) EP4219546A3 (en)
JP (5) JP6298455B2 (en)
KR (4) KR102663134B1 (en)
CN (2) CN110835624A (en)
AU (4) AU2013267525B2 (en)
BR (1) BR112014029095A2 (en)
CA (1) CA2873131A1 (en)
DK (1) DK2875047T5 (en)
EA (2) EA028790B1 (en)
ES (1) ES2940900T3 (en)
FI (1) FI2875047T3 (en)
HU (1) HUE061479T2 (en)
IL (4) IL279922B2 (en)
MX (1) MX360359B (en)
PL (1) PL2875047T3 (en)
SG (2) SG11201407652RA (en)
TW (2) TW201823460A (en)
WO (1) WO2013181253A1 (en)
ZA (1) ZA201408289B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201823460A (en) 2012-05-29 2018-07-01 美商再生元醫藥公司 Production cell strain enhancer
TW201803981A (en) 2016-04-20 2018-02-01 再生元醫藥公司 Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG10202010155YA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3541365A1 (en) 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
CN111356471A (en) 2017-11-20 2020-06-30 济世发展生物药业有限公司 Abutip formulation comprising lysine salt as tonicity modifier and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60211329T2 (en) 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. ISOLATION OF SEPARATED PROTEINS EXPRESSING CELLS
JP4817657B2 (en) 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Inducible eukaryotic expression system
US20040170622A1 (en) 2002-08-30 2004-09-02 President And Fellows Of Harvard College Methods and compositions for modulating XBP-1 activity
JP2007500016A (en) * 2003-06-11 2007-01-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド Method for increasing protein production in culture
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2561702C (en) * 2004-03-31 2018-05-15 Centocor, Inc. Methods for altering protein production rates
LT1781698T (en) * 2004-07-20 2016-09-26 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
RU2007106442A (en) * 2004-09-02 2008-10-10 Вайет (Us) SYSTEMS AND METHODS FOR PRODUCING PROTEINS
AU2005284798B2 (en) 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
EP1964922A1 (en) * 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
WO2008115596A2 (en) 2007-03-21 2008-09-25 Danisco Us, Inc., Genencor Division Over expression of foldases and chaperones improves protein production
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2010535781A (en) * 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー Treatment for obesity
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
US20110281301A1 (en) * 2007-11-13 2011-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg The secretory capacity in host cells
US20090247609A1 (en) * 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
WO2009155008A1 (en) 2008-05-28 2009-12-23 Bayer Healthcare Llc Methods and compositions for production of recombinant protein in hbx-expressing mammalian cells
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0902180D0 (en) 2009-02-10 2009-03-25 Ucb Pharma Sa Method for producing protein
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
CN102459603B (en) 2009-06-02 2013-11-06 瑞泽恩制药公司 Fucosylation-deficient cells
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
JO3274B1 (en) * 2009-12-24 2018-09-16 Regeneron Pharma Human Antibodies To Human Angiopoietin-Like Protein 4
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
TW201823460A (en) 2012-05-29 2018-07-01 美商再生元醫藥公司 Production cell strain enhancer
AU2013337247B2 (en) 2012-11-05 2018-08-09 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

Also Published As

Publication number Publication date
PL2875047T3 (en) 2023-05-29
TWI641687B (en) 2018-11-21
AU2019203780B2 (en) 2021-07-01
KR20220003165A (en) 2022-01-07
AU2018201094B2 (en) 2019-06-20
KR102663134B1 (en) 2024-05-03
ZA201408289B (en) 2016-09-28
KR102126210B1 (en) 2020-06-25
US10351622B2 (en) 2019-07-16
JP2020022514A (en) 2020-02-13
IL265867A (en) 2019-06-30
MX2014014630A (en) 2015-02-12
CN110835624A (en) 2020-02-25
JP2018108094A (en) 2018-07-12
DK2875047T5 (en) 2024-10-14
JP2023153268A (en) 2023-10-17
KR20150015492A (en) 2015-02-10
EA028790B1 (en) 2017-12-29
KR20200074273A (en) 2020-06-24
US20160304598A1 (en) 2016-10-20
US9193786B2 (en) 2015-11-24
IL279922B1 (en) 2025-05-01
JP7037535B2 (en) 2022-03-16
AU2019203780A1 (en) 2019-06-20
US20150299310A1 (en) 2015-10-22
JP7382383B2 (en) 2023-11-16
US9228012B2 (en) 2016-01-05
US20170291938A1 (en) 2017-10-12
FI2875047T3 (en) 2023-03-30
US9382315B2 (en) 2016-07-05
US9688751B2 (en) 2017-06-27
EP3564262A1 (en) 2019-11-06
KR20230065370A (en) 2023-05-11
EA201492242A1 (en) 2015-05-29
USRE48651E1 (en) 2021-07-20
US20150299309A1 (en) 2015-10-22
US20150353634A1 (en) 2015-12-10
KR102346867B1 (en) 2022-01-04
EP2875047A1 (en) 2015-05-27
AU2013267525B2 (en) 2017-11-16
AU2021240303B2 (en) 2025-02-27
EP2875047B1 (en) 2023-01-25
AU2018201094A1 (en) 2018-03-15
IL279922A (en) 2021-03-01
JP2015518728A (en) 2015-07-06
ES2940900T3 (en) 2023-05-12
BR112014029095A2 (en) 2017-07-18
DK2875047T3 (en) 2023-03-27
IL279922B2 (en) 2025-09-01
JP6298455B2 (en) 2018-03-20
US9079954B2 (en) 2015-07-14
EP4219546A2 (en) 2023-08-02
IL320011A (en) 2025-06-01
WO2013181253A1 (en) 2013-12-05
US20150175688A1 (en) 2015-06-25
AU2013267525A1 (en) 2014-12-11
US10227401B2 (en) 2019-03-12
TW201402815A (en) 2014-01-16
EP4219546A3 (en) 2023-08-23
SG10201606654XA (en) 2016-10-28
KR102528950B1 (en) 2023-05-08
US10611831B2 (en) 2020-04-07
TW201823460A (en) 2018-07-01
MX360359B (en) 2018-10-30
HUE061479T2 (en) 2023-07-28
JP6622334B2 (en) 2019-12-18
US20130323788A1 (en) 2013-12-05
US20190270800A1 (en) 2019-09-05
IL235573A0 (en) 2015-01-29
EA201792213A1 (en) 2018-01-31
JP2022044609A (en) 2022-03-17
HK1205137A1 (en) 2015-12-11
CN104350068A (en) 2015-02-11
AU2021240303A1 (en) 2021-10-28
CA2873131A1 (en) 2013-12-05
IL235573B (en) 2019-09-26
CN104350068B (en) 2019-12-03

Similar Documents

Publication Publication Date Title
SG11201407652RA (en) Production cell line enhancers
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201909777YA (en) Modulatory polynucleotides
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201909011PA (en) Niraparib compositions
SG11201909203WA (en) Tissue selective transgene expression
SG11201804400SA (en) Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
SG11201807188VA (en) Modified cells for immunotherapy
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201407508RA (en) Encoding and decoding based on blending of sequences of samples along time
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201808398PA (en) Cell line for recombinant protein and/or viral vector production
SG11201805119QA (en) Methods to determine tumor gene copy number by analysis of cell-free dna
SG11201807912SA (en) Vaccine against rsv
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201407505XA (en) Aptamer-based multiplexed assays
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers